Sputnik V Covid-19 vaccine gets nod for clinical trials in India

China’s Sinopharm offers experimental COVID-19 vaccines to students WSJ

However, no vaccine has yet been licensed."In China, there are four vaccines that are in the final phase of clinical trials, with some of them showing promising results, such as Sinovac, according to the scientific journal The Lancet", continues the journalist.

In a Phase-3 test and Phase-2 trial, two fabricators are now in the run, and more players will join. "In a nutshell, safety, efficacy and distribution without discrimination of COVID-19 vaccines are as important as its accessibility".

Last week, the Director-General of the National Emergency Crisis and Disasters Management Authority (NCEMA), Obaid Rashid Al Shamsi, has taken the first dose of COVID-19 vaccine along with frontline health workers.

Sheikh Abdullah tweeted, "COVID-19 vaccine is our way to return to normal life". Union Health Minister Dr Harsh Vardhan has asserted that 400 million vaccines will be made available by next year.

Dr Sander van der Linden, who is director of the Cambridge Social Decision-Making Lab and one of the authors on the study, said: 'We find a clear link between believing coronavirus conspiracies and hesitancy around any future vaccine.

The detailed 148-page plan notes that the groups of people getting a vaccine first will be reevaluated over time. It is expected that the Corona vaccine will be developed in the country at the end of the year or early next year.

We need to talk about vaccines; we need to vaccinate enough people - protection and protection can be accomplished safely with a vaccine. "Effective governance is also required to carry out the judicious accessibility of the vaccine, which we have already".

The EpiVacCorona is a peptide synthetic vaccine based on a recombinant virus. The group, headed by Niti Aayog member Dr V K Paul and co-chaired by health secretary Rajesh Bhushan, has studied allocations for early-phase vaccinations proposed by the CDC, Atlanta and the WHO while charting India's framework for equitable and need-based access.

Elaborating on the status of the vaccine development during HEAL-Thy Samvaad, Mr Samir Deb, pharmaceutical professional, consultant vaccine & public affairs consultant, South East Asia, said, "Vaccine development is a burning issue across the world now. Ensuring accessibility for 80 per cent of the population is a huge task indeed".



Other news